Oppenheimer starts Allogene with Outperform rating, $45 price target. Oppenheimer analyst Mark Breidenbach initiated coverage of Allogene Therapeutics with an Outperform rating and $45 price target. The company is developing allogeneic products which could address “significant” issues surrounding today’s autologous CARTs including manufacturing bandwidth, cost and consistency, Breidenbach tells investors in a research note. He believes Allogene has the wherewithal to make off-the-shelf CAR-Ts a “commercial reality” and points out it has “multiple de-risking data readouts” over the next 12-18 months.
Thursday, May 2, 2019
Bluebird Bio reports Q1 EPS ($2.99) , consensus ($2.80)
Reports Q1 revenue $12.5M, consensus $13.24M. Cash, cash equivalents and marketable securities as of March 31, 2019 and December 31, 2018 were $1.73 billion and $1.89 billion, respectively. The decrease in cash, cash equivalents and marketable securities is primarily related to cash used in support of normal operating activities and cash used to purchase property, plant and equipment as the company continues the buildout of its manufacturing facility in Durham, North Carolina.
Alder Biopharmaceuticals reports Q1 EPS ($1.63), consensus ($1.03)
As of March 31, Alder had $498.5M in cash, cash equivalents, investments and restricted cash, compared to $412.4M as of December 31, 2018.
Herbalife Nutrition cuts FY19 adj. EPS view to $2.50-$2.95 from $2.92-$3.32
Due to the recent slowdown in China, the company is revising full year 2019 volume point guidance to a range of 0.5% – 6.5% growth, net sales guidance to a range of (1.0%) – 5.0%, as well as reported and adjusted diluted EPS guidance to a range of $2.19 – $2.64 and $2.50 – $2.95, respectively.
Magellan Health backs 2019 adjusted EPS view $3.70-$4.69, consensus $3.92
Lowers 2019 revenue view to $7.0M-$7.2M from $7.2B-$7.5B, consensus $7.22B.
Subscribe to:
Posts (Atom)